20:30:35 EDT Fri 19 Apr 2024
Enter Symbol
or Name

Q:CSTL - CASTLE BIOSCIENCES INC - http://www.castelle.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CSTL - Q2.518.64·,3612,35419.04  19.35  18.9026.70  9.260116:03:18Apr 1115 min RT 2¢

Recent Trades - Last 10 of 2354
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-11 07:00U:CSTLNews ReleaseCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
2024-04-10 17:00U:CSTLNews ReleaseCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
2024-04-10 07:00U:CSTLNews ReleaseCastle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
2024-04-04 16:30U:CSTLNews ReleasePresentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx(TM)-Melanoma and DecisionDx(TM)-SCC Tests on the Management of Patients with Skin Cancer
2024-04-02 07:00U:CSTLNews ReleaseCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-27 17:00U:CSTLNews ReleaseCastle Biosciences Announces Updates to its Board of Directors
2024-03-25 07:00U:CSTLNews ReleaseCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
2024-03-22 16:30U:CSTLNews ReleaseLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx(TM)-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
2024-03-19 07:00U:CSTLNews ReleaseLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx(TM)-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
2024-03-15 16:30U:CSTLNews ReleaseNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix(TM) Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
2024-03-12 07:00U:CSTLNews ReleaseCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
2024-03-08 16:30U:CSTLNews ReleaseCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
2024-03-07 07:00U:CSTLNews ReleaseIn Novel Cohort, New Data Confirms DecisionDx(TM)-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
2024-02-28 16:05U:CSTLNews ReleaseCastle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
2024-02-26 07:00U:CSTLNews ReleaseStudy Finds DecisionDx(TM)-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
2024-02-07 07:00U:CSTLNews ReleaseCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
2024-01-18 07:00U:CSTLNews ReleaseNew Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences ¢ € ™ DecisionDx ‚ ®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
2024-01-14 04:30U:CSTLNews ReleaseCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii ‚ ®
2024-01-09 07:00U:CSTLNews ReleaseCastle Biosciences ¢ € ™ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
2024-01-07 20:00U:CSTLNews ReleaseCastle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results